Beyond personalized radiation dose planning, we could cautiously assume that whole brain or large field RT rather than focal RT might be an effective personalized treatment option with excellent in-field control and prolonged survival in patients with IDH-wildtype ATM mut(+) high-grade glioma. The gene discussed is ATM; the disease is central nervous system cancer.